Analytical validation of the Signatera RUO Assay AACR 2018
The identification of tumor mutations in circulating cell-free DNA (cfDNA) holds great potential for the noninvasive detection of cancer relapse.
The identification of tumor mutations in circulating cell-free DNA (cfDNA) holds great potential for the noninvasive detection of cancer relapse.